Anti-LCMV surface glycoprotein [M28], Human IgG1, Fc Silent™, kappa
Catalogue Number: AB05114-10.3-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | LCMV surface GP; lineage I Lassa fever virus; lineage I LASV; LASV; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2; 18.5C-M28 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Human |
| Clone: | M28 |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated by introducing two mutations (S32R and R55 insertion) into the sequence of the parent clone 18.5C (an isolate from a human survivor of Lassa fever). |
| Application: | ELISA, EM, NT, InVitroA, InVivoA |
Additional Text
Purification
Purified
UniProt ID
P07399
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Short Description
This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Application Notes
The original antibody (human IgG1) was generated and confirmed to specifically recognize the target via ELISA. A Fab version of it was generated and tested for neutralization. This antibody demonstrated potent in vitro neutralization (IC₅₀ ~ 0.51 µg/mL) and both prophylactic and therapeutic efficacy in a murine chronic LCMV model, with complete viral clearance and protection from weight loss. Furthermore, this antibody enabled high-resolution cryoEM of the LCMV GP trimer in both apo and Fab-bound states, defining a quaternary, pre-fusion-specific epitope (Moon-Walker et al., 2023; PMID: 36990092). In vitro, this antibody fully neutralized cell-free LCMV at 5 µg/mL and was used to demonstrate that ~50% of viral spread occurs via antibody-resistant, direct cell-to-cell nanotube transfer (Byford et al., 2024; PMID: 39578605).
AB05114-10.3-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations